Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Dec 2024 value amounting to $68.6 million.

  • Day One Biopharmaceuticals' Accumulated Expenses rose 37.00% to $48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.2 million, marking a year-over-year increase of 37.00%. This contributed to the annual value of $68.6 million for FY2024, which is 158.73% up from last year.
  • As of FY2024, Day One Biopharmaceuticals' Accumulated Expenses stood at $68.6 million, which was up 158.73% from $26.5 million recorded in FY2023.
  • Over the past 5 years, Day One Biopharmaceuticals' Accumulated Expenses peaked at $68.6 million during FY2024, and registered a low of $15.9 million during FY2022.
  • For the 3-year period, Day One Biopharmaceuticals' Accumulated Expenses averaged around $37.0 million, with its median value being $26.5 million (2023).
  • Data for Day One Biopharmaceuticals' Accumulated Expenses shows a peak YoY skyrocketed of 158.73% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Day One Biopharmaceuticals' Accumulated Expenses stood at $15.9 million in 2022, then soared by 66.29% to $26.5 million in 2023, then soared by 158.73% to $68.6 million in 2024.